company background image
GSKC

GlaxoSmithKline Consumer Healthcare Pakistan KASE:GSKCH Stock Report

Last Price

PK₨234.00

Market Cap

PK₨27.4b

7D

-2.1%

1Y

3.4%

Updated

16 May, 2022

Data

Company Financials
GSKCH fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance5/6
Financial Health5/6
Dividends0/6

GSKCH Stock Overview

GlaxoSmithKline Consumer Healthcare Pakistan Limited engages in the research and development, manufacture, marketing, and sale of consumer healthcare products primarily in Pakistan.

GlaxoSmithKline Consumer Healthcare Pakistan Competitors

 

 

 

 

 

 

 

 

 

 

 

 

Price History & Performance

Summary of all time highs, changes and price drops for GlaxoSmithKline Consumer Healthcare Pakistan
Historical stock prices
Current Share PricePK₨234.00
52 Week HighPK₨303.96
52 Week LowPK₨210.10
Beta1.04
1 Month Change-7.49%
3 Month Change-10.77%
1 Year Change3.38%
3 Year Change23.97%
5 Year Change-20.14%
Change since IPO259.70%

Recent News & Updates

Shareholder Returns

GSKCHPK Personal ProductsPK Market
7D-2.1%-1.5%-3.3%
1Y3.4%-21.0%-9.9%

Return vs Industry: GSKCH exceeded the PK Personal Products industry which returned -21% over the past year.

Return vs Market: GSKCH exceeded the PK Market which returned -9.9% over the past year.

Price Volatility

Is GSKCH's price volatile compared to industry and market?
GSKCH volatility
GSKCH Average Weekly Movement3.8%
Personal Products Industry Average Movement6.0%
Market Average Movement5.7%
10% most volatile stocks in PK Market8.8%
10% least volatile stocks in PK Market3.6%

Stable Share Price: GSKCH is less volatile than 75% of PK stocks over the past 3 months, typically moving +/- 4% a week.

Volatility Over Time: GSKCH's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2015459Farhan Haroonhttps://www.pk-consumerhealthcare.gsk.com

GlaxoSmithKline Consumer Healthcare Pakistan Limited engages in the research and development, manufacture, marketing, and sale of consumer healthcare products primarily in Pakistan. The company offers products in the areas of pain relief under the Panadol and IODEX brands; oral health under the Sensodyne and Parodontax brand names; respiratory health under the Panadol CF, Sancos, T-Day, Tandegyl, and Actified brands; nutrition and gastrointestinal health under the CaC-1000 PLUS, ENO, and Horlicks brand names; and skin health under the Physiogel, Hydrozole, SunBlock 60, Lamisil, Acne Aid, Duofilm, Brevoxyl, and Oilatum brands. It also exports its products.

GlaxoSmithKline Consumer Healthcare Pakistan Fundamentals Summary

How do GlaxoSmithKline Consumer Healthcare Pakistan's earnings and revenue compare to its market cap?
GSKCH fundamental statistics
Market CapPK₨27.39b
Earnings (TTM)PK₨2.13b
Revenue (TTM)PK₨24.16b

12.8x

P/E Ratio

1.1x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
GSKCH income statement (TTM)
RevenuePK₨24.16b
Cost of RevenuePK₨17.51b
Gross ProfitPK₨6.65b
Other ExpensesPK₨4.52b
EarningsPK₨2.13b

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

n/a

Earnings per share (EPS)18.23
Gross Margin27.53%
Net Profit Margin8.83%
Debt/Equity Ratio1.7%

How did GSKCH perform over the long term?

See historical performance and comparison

Valuation

Is GlaxoSmithKline Consumer Healthcare Pakistan undervalued compared to its fair value and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • PE vs Industry

  • PE vs Market

  • PEG Ratio

  • PB vs Industry


12.83x

Price to Earnings (PE) ratio

Share Price vs. Fair Value

Below Fair Value: GSKCH (PKR234) is trading above our estimate of fair value (PKR9.37)

Significantly Below Fair Value: GSKCH is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: GSKCH is good value based on its PE Ratio (12.8x) compared to the Asian Personal Products industry average (20.9x).

PE vs Market: GSKCH is poor value based on its PE Ratio (12.8x) compared to the PK market (5.7x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate GSKCH's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: GSKCH is overvalued based on its PB Ratio (4.1x) compared to the XA Personal Products industry average (1.8x).


Future Growth

How is GlaxoSmithKline Consumer Healthcare Pakistan forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


14.0%

Forecasted Household industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as GlaxoSmithKline Consumer Healthcare Pakistan has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has GlaxoSmithKline Consumer Healthcare Pakistan performed over the past 5 years?

Past Performance Score

5/6

Past Performance Score 5/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


19.5%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: GSKCH has a high level of non-cash earnings.

Growing Profit Margin: GSKCH's current net profit margins (8.8%) are higher than last year (6.4%).


Past Earnings Growth Analysis

Earnings Trend: GSKCH's earnings have grown by 19.5% per year over the past 5 years.

Accelerating Growth: GSKCH's earnings growth over the past year (69.1%) exceeds its 5-year average (19.5% per year).

Earnings vs Industry: GSKCH earnings growth over the past year (69.1%) exceeded the Personal Products industry 11%.


Return on Equity

High ROE: GSKCH's Return on Equity (31.8%) is considered high.


Financial Health

How is GlaxoSmithKline Consumer Healthcare Pakistan's financial position?

Financial Health Score

5/6

Financial Health Score 5/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: GSKCH's short term assets (PKR10.0B) exceed its short term liabilities (PKR6.9B).

Long Term Liabilities: GSKCH's short term assets (PKR10.0B) exceed its long term liabilities (PKR294.3M).


Debt to Equity History and Analysis

Debt Level: GSKCH has more cash than its total debt.

Reducing Debt: Insufficient data to determine if GSKCH's debt to equity ratio has reduced over the past 5 years.

Debt Coverage: GSKCH's debt is well covered by operating cash flow (1386.1%).

Interest Coverage: GSKCH earns more interest than it pays, so coverage of interest payments is not a concern.


Balance Sheet


Dividend

What is GlaxoSmithKline Consumer Healthcare Pakistan current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate GSKCH's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate GSKCH's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if GSKCH's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if GSKCH's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: GSKCH is not paying a notable dividend for the PK market.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as GSKCH has not reported any payouts.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.6yrs

Average management tenure


CEO

Farhan Haroon

1.08yrs

Tenure

Mr. Farhan Muhammad Haroon serves as Chief Executive Officer and Executive Director at GlaxoSmithKline Consumer Healthcare Pakistan Limited since April 1, 2021. Mr. Haroon served as Chief Financial Officer...


Leadership Team

Experienced Management: GSKCH's management team is not considered experienced ( 1.6 years average tenure), which suggests a new team.


Board Members

Experienced Board: GSKCH's board of directors are not considered experienced ( 1.6 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

GlaxoSmithKline Consumer Healthcare Pakistan Limited's employee growth, exchange listings and data sources


Key Information

  • Name: GlaxoSmithKline Consumer Healthcare Pakistan Limited
  • Ticker: GSKCH
  • Exchange: KASE
  • Founded: 2015
  • Industry: Personal Products
  • Sector: Household
  • Implied Market Cap: PK₨27.391b
  • Shares outstanding: 117.05m
  • Website: https://www.pk-consumerhealthcare.gsk.com

Number of Employees


Location

  • GlaxoSmithKline Consumer Healthcare Pakistan Limited
  • 35, Dockyard Road
  • West Wharf
  • Karachi
  • 74000
  • Pakistan

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/05/16 00:00
End of Day Share Price2022/05/16 00:00
Earnings2021/12/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.